CompoundIQ

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

OtherIntermediateLow Risk

Bromantane

Also known as: Ladasten

Bromantane is a unique actoprotector developed in Russia that combines psychostimulant and anxiolytic properties. Unlike traditional stimulants, it upregulates dopamine and serotonin synthesis enzymes rather than depleting neurotransmitters.

Evidence42/100 — Emerging

Risk Level

Low Risk

Difficulty

Intermediate
CAS Number87913-26-6
Molecular FormulaC16H20BrN
ClassOther
CategoryOther Performance Compounds

Mechanism of Action

Bromantane upregulates tyrosine hydroxylase and tryptophan hydroxylase gene expression, increasing the synthesis capacity for dopamine and serotonin. This is fundamentally different from releasing agents or reuptake inhibitors. It also has immunomodulatory properties and enhances physical work capacity under stress conditions.

Dosing Research

Russian clinical dose: 50-100 mg/day orally. Half-life approximately 11 hours. Effects develop gradually over 2-3 days. Typically used in 2-4 week cycles. Was briefly an approved pharmaceutical in Russia.

Side Effects & Risks

Generally well-tolerated. Rare reports of allergic reactions and mild GI discomfort. Banned by WADA since 1997. Non-addictive based on available data. Limited Western safety studies.

Research Studies

Disclaimer

CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.

Send Feedback

Help us improve CompoundIQ